Overall market sentiment has been neutral on Cue Biopharma Inc (CUE) stock lately. CUE receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With CUE Stock Today?
Cue Biopharma Inc (CUE) stock is up 1.99% while the S&P 500 has fallen -0.49% as of 11:30 AM on Monday, Jan 25. CUE has gained $0.28 from the previous closing price of $14.07 on volume of 199,613 shares. Over the past year the S&P 500 has risen 17.85% while CUE has fallen -7.48%. CUE lost -$1.57 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Cue Biopharma Inc click here.
More About Cue Biopharma Inc
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers.
Click Here to get the full Stock Score Report on Cue Biopharma Inc (CUE) Stock.
